TR201907907T4 - Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. - Google Patents

Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. Download PDF

Info

Publication number
TR201907907T4
TR201907907T4 TR2019/07907T TR201907907T TR201907907T4 TR 201907907 T4 TR201907907 T4 TR 201907907T4 TR 2019/07907 T TR2019/07907 T TR 2019/07907T TR 201907907 T TR201907907 T TR 201907907T TR 201907907 T4 TR201907907 T4 TR 201907907T4
Authority
TR
Turkey
Prior art keywords
benralizumab
antigen
binding fragment
fev1
patient
Prior art date
Application number
TR2019/07907T
Other languages
English (en)
Turkish (tr)
Inventor
Ward Christine
Roskos Lorin
Wang Bing
Raible Donald
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR201907907T4 publication Critical patent/TR201907907T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
TR2019/07907T 2013-08-12 2014-08-07 Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. TR201907907T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12

Publications (1)

Publication Number Publication Date
TR201907907T4 true TR201907907T4 (tr) 2019-06-21

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07907T TR201907907T4 (tr) 2013-08-12 2014-08-07 Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri.

Country Status (26)

Country Link
US (1) US9441046B2 (enExample)
EP (4) EP3520811B1 (enExample)
JP (4) JP6746496B2 (enExample)
KR (1) KR102337599B1 (enExample)
CN (2) CN111588849A (enExample)
AU (2) AU2014306959B2 (enExample)
BR (1) BR112016002317A8 (enExample)
CA (1) CA2917603C (enExample)
CY (2) CY1122033T1 (enExample)
DK (2) DK3033104T3 (enExample)
ES (2) ES2866426T3 (enExample)
HK (1) HK1222559A1 (enExample)
HR (2) HRP20190920T1 (enExample)
HU (2) HUE043497T2 (enExample)
LT (2) LT3033104T (enExample)
ME (1) ME03403B (enExample)
MX (2) MX381102B (enExample)
PL (2) PL3033104T3 (enExample)
PT (2) PT3033104T (enExample)
RS (2) RS58711B1 (enExample)
RU (1) RU2703568C2 (enExample)
SG (1) SG11201600483QA (enExample)
SI (2) SI3033104T1 (enExample)
SM (2) SMT202100152T1 (enExample)
TR (1) TR201907907T4 (enExample)
WO (1) WO2015023507A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023504A1 (en) 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK3072525T3 (en) * 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
KR101615474B1 (ko) * 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
WO2015023504A1 (en) 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab

Also Published As

Publication number Publication date
ES2733602T3 (es) 2019-12-02
EP3033104A2 (en) 2016-06-22
RU2016108809A (ru) 2017-09-18
CN111588849A (zh) 2020-08-28
MX381102B (es) 2025-03-12
JP2022120010A (ja) 2022-08-17
LT3033104T (lt) 2019-06-25
JP6746496B2 (ja) 2020-08-26
PT3520811T (pt) 2021-03-15
JP2020125304A (ja) 2020-08-20
KR20160043049A (ko) 2016-04-20
MX2021003826A (es) 2021-05-27
HK1225300A1 (en) 2017-09-08
AU2014306959B2 (en) 2019-11-21
HUE053627T2 (hu) 2021-07-28
EP3520811A1 (en) 2019-08-07
CY1124399T1 (el) 2022-07-22
BR112016002317A2 (pt) 2017-12-12
KR102337599B1 (ko) 2021-12-10
SMT201900311T1 (it) 2019-07-11
AU2020201277A1 (en) 2020-03-12
EP4579236A3 (en) 2025-09-17
PL3033104T3 (pl) 2019-09-30
DK3520811T3 (da) 2021-03-22
HUE043497T2 (hu) 2019-08-28
US9441046B2 (en) 2016-09-13
WO2015023507A2 (en) 2015-02-19
EP3520811B1 (en) 2020-12-30
HRP20190920T1 (hr) 2019-07-12
CA2917603C (en) 2023-05-16
JP2016527325A (ja) 2016-09-08
EP4579236A2 (en) 2025-07-02
ME03403B (me) 2020-01-20
EP4636400A2 (en) 2025-10-22
EP3033104A4 (en) 2017-03-22
RU2016108809A3 (enExample) 2018-06-18
SMT202100152T1 (it) 2021-05-07
WO2015023507A3 (en) 2015-04-09
CY1122033T1 (el) 2020-10-14
EP3875487A1 (en) 2021-09-08
SG11201600483QA (en) 2016-02-26
EP3033104B1 (en) 2019-04-03
US20150044203A1 (en) 2015-02-12
WO2015023507A8 (en) 2015-09-24
CA2917603A1 (en) 2015-02-19
HK1222559A1 (zh) 2017-07-07
MX2016001384A (es) 2016-08-03
HRP20210406T1 (hr) 2021-04-30
AU2014306959A1 (en) 2016-02-04
PT3033104T (pt) 2019-06-27
BR112016002317A8 (pt) 2018-06-12
RS58711B1 (sr) 2019-06-28
RS61565B1 (sr) 2021-04-29
ES2866426T3 (es) 2021-10-19
DK3033104T3 (da) 2019-06-17
RU2703568C2 (ru) 2019-10-21
PL3520811T3 (pl) 2021-08-02
SI3033104T1 (sl) 2019-06-28
LT3520811T (lt) 2021-03-25
CN105451769A (zh) 2016-03-30
JP2024129140A (ja) 2024-09-26
SI3520811T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
TR201907907T4 (tr) Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri.
AU2020202564A1 (en) Methods for improving asthma symptoms using benralizumab
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40058739A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40013807A (en) Methods for improving asthma symptoms using benralizumab
HK40013807B (en) Methods for improving asthma symptoms using benralizumab
HK40035227A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK1225303B (en) Methods for improving asthma symptoms using benralizumab